FFCD-9102

Regimen

Experimental
continuation of chemoradiotherapy (cisplatin/5-FU + RT)
Control
chemoradiotherapy followed by surgery

Population

Operable T3N0-1M0 thoracic esophageal cancer (predominantly squamous) who responded to induction chemoradiotherapy

Key finding

2y OS 34% (surgery) vs 40% (CRT-continuation), HR 0.90, P=0.44 (NS); 3-month mortality 9.3% vs 0.8% (P=0.002). No survival benefit from adding surgery to CRT-response in ESCC.

Source: PMID 17401004

Timeline

    Guideline citations

    • NCCN ESOPHAGEAL (p.62)